Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
---|---|---|---|
USD 114.88 Billion | USD 164.93 Billion | 4.1% | 2023 |
According to the report published by Zion Market Research, the global Small Molecule API Market size was valued at USD 114.88 Billion in 2023 and is predicted to reach USD 164.93 Billion by the end of 2032. The market is expected to grow with a CAGR of 4.1% during the forecast period. The report analyzes the global Small Molecule API Market's growth drivers, restraints, and impact on demand during the forecast period. It will also help navigate and explore the arising opportunities in the Small Molecule API industry.
Small molecules API are usually composed of 20-100 atoms that are well characterized and easily purified & analyzed. Small molecules are extensively used to treat several diseases & conditions and are diverse in their mechanism of action. Owing to their typical physicochemical properties and small size they can be effective allosteric modifiers & enzyme inhibitors and can target intracellular receptors or extracellular proteins in the central nervous system, nuclei, and cytosol.
The global small molecule API market is growing at a lucrative rate. Factors that are contributing to the growth of the global market are rise in prevalence of chronic & infectious diseases, an increase in the number of contract research manufacturers supporting the drug discovery & development projects of pharmaceuticals, the resurgence of small molecule API, and growing research & development on the small molecule for drug development. The use of small molecules as API is of great significance to the patients and industry. Small molecules have several advantages over the use of large molecule API.
A small molecule can be engineered to provide a strong therapeutic effect even with a small dose that can be below 10 mg or even into micrograms. Also, the analytical technology of the small molecules ensures reproducibility, efficacy & quality, and is highly refined. In addition to this, small molecules can be easily formulated into doses that can be delivered orally. This offers better compliance and low cost of administration as compared to injectable which is the principal route of administration of large molecules.
All these factors have led to a rise in demand for the use of small molecules thereby fueling the growth of the global small molecule API market. Moreover, as compared to clinical trials involving large molecule API, those involving small molecule API are less expensive and simpler which in turn is contributing to the growth of the global market. Furthermore, factors such as an increase in mergers & acquisitions for portfolio expansion and a rise in outsourcing of the drug discovery may lead to ample opportunities for the growth of the global small molecule API market during the forecast period. However, stringent regulatory policies and the development of advanced therapies may hinder the growth of the global small molecule API market.
The healthcare industry is under immense pressure due to the current pandemic situation. To control the rapid spread of disease, strict lockdown and restriction on movement is been enforced across several countries. The operational and development process is been halted temporarily and R&D activities are also been ceased. Additionally, the pandemic has also hampered the clinical trials due to stay-at-home orders and the shifting of most of the healthcare workers towards the treatment of Covid-19 patients. All these factors have impacted the growth of the global small molecule API market during the pandemic. However, in the forthcoming years, the market may speed up to recover from the effects of the pandemic.
The global small molecule API market is categorized based on production, molecule type, application, therapeutic area, and region.
Based on the production, the global small molecule API market is segregated into outsourcing and captive/in-house.
Based on the molecule type, the global market is split into HPAPI and standard API.
The application segment is categorized into commercial and clinical.
The therapeutic area comprises cardiovascular diseases, general health, urology, oncology, respiratory disorders, neurology, metabolic disorders, infectious diseases, and others.
Report Attributes | Report Details |
---|---|
Report Name | Small Molecule API Market |
Market Size in 2023 | USD 114.88 Billion |
Market Forecast in 2032 | USD 164.93 Billion |
Growth Rate | CAGR of 4.1% |
Number of Pages | 215 |
Key Companies Covered | Pfizer, Albany Molecular Research Inc., GILEAD Science Inc, Bristol-Myers Squibb, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd., GlaxoSmithKline PLC, Novartis AG, Johnson Matthey, Boehringer Ingelheim GmbH, and Sanofi S.A., among others |
Segments Covered | By production, By molecule type, By application, By therapeutic area and By Region |
Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
Base Year | 2023 |
Historical Year | 2018 to 2022 |
Forecast Year | 2024 - 2032 |
Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
Geographically, North America is predicted to account for the largest share in the global small molecule API market during the forecast period. An increase in outsourcing of the drug discovery projects, rise in investment in research & development of drugs, and increase in the prevalence of infectious & chronic diseases are some of the major factors that are boosting the growth of the market in this region. Asia Pacific is estimated to grow at the highest CAGR value due to rapidly expanding API manufacturing units in China and favorable Indian government policy such as 100 percent FDI attracting major players for the expansion of business. Europe is also expected to contribute to a significant share in the market.
Some of the key players operating in the global small molecule API market are
By production
By molecule type
By application
By therapeutic area
FrequentlyAsked Questions
Factors that are contributing to the growth of the global market are a rise in prevalence of chronic & infectious diseases, an increase in the number of contract research manufacturers supporting the drug discovery & development projects of pharmaceuticals, the resurgence of small molecule API, and growing research & development on the small molecule for drug development. Furthermore, factors such as an increase in mergers & acquisitions for portfolio expansion and a rise in outsourcing of the drug discovery may lead to ample opportunities for the growth of the global small molecule API market during the forecast period.
Some of the key players operating in the global small molecule API market are Pfizer, Albany Molecular Research Inc., GILEAD Science Inc, Bristol-Myers Squibb, Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd., GlaxoSmithKline PLC, Novartis AG, Johnson Matthey, Boehringer Ingelheim GmbH, and Sanofi S.A., among others.
Geographically, North America is predicted to account for the largest share in the global small molecule API market during the forecast period. An increase in outsourcing of the drug discovery projects, rise in investment in research & development of drugs, and increase in the prevalence of infectious & chronic diseases are some of the major factors that are boosting the growth of the market in this region.
HappyClients
Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651
3rd Floor,
Mrunal Paradise, Opp Maharaja Hotel,
Pimple Gurav, Pune 411061,
Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008
US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com
We have secured system to process your transaction.
Our support available to help you 24 hours a day, five days a week.
Monday - Friday: 9AM - 6PM
Saturday - Sunday: Closed